CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Invitris is revolutionizing phage therapy with its Phactory™ platform, enabling the scalable and personalized production of bacteriophages to combat drug-resistant bacteria. This innovative approach aims to provide targeted treatments while minimizing risks to the patient's microbiome.
The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome.
Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria.
Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria.
However, the current production processes for phages pose considerable biosafety concerns and are often relatively inef…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
